|
| related topics |
| {regulation, government, change} |
| {product, market, service} |
| {product, candidate, development} |
| {control, financial, internal} |
| {cost, regulation, environmental} |
| {competitive, industry, competition} |
| {tax, income, asset} |
| {personnel, key, retain} |
| {property, intellectual, protect} |
| {customer, product, revenue} |
| {acquisition, growth, future} |
|
|
A reduction in research and development budgets at pharmaceutical and biotechnology companies may adversely affect our business.
Our future success depends on our ability to keep pace with rapid technological changes that could make our services and products less competitive or obsolete.
The CRO services industry is highly competitive.
The loss of our key personnel could adversely affect our business.
Any failure by us to comply with existing regulations could harm our reputation and operating results.
Proposed and future legislation or regulations might increase the cost of our business or limit our service or product offerings.
Our business uses biological and hazardous materials, which could injure people or violate laws, resulting in liability that could adversely impact our financial condition and business.
The majority of our customers contracts can be terminated upon short notice.
Our Products business depends on our intellectual property.
We might incur substantial expense to develop products that are never successfully developed and commercialized.
We dose human volunteers with new drug candidates in our clinical operations.
Providing CRO services create a risk of liability.
If we are unable to attract suitable willing volunteers for our clinical trials, our clinical research business might suffer.
We may expand our business through acquisitions.
Changes in government regulation or in practices relating to the pharmaceutical industry could change the need for the services we provide.
Privacy regulations could increase our costs or limit our services.
We might lose business opportunities as a result of healthcare reform.
We have experienced periods of losses on our operating activities.
We continue to experience operating losses in our Baltimore Phase I clinic.
The outsourcing trend in the biotechnology and pharmaceutical industries may decrease, which could slow our growth.
Accounting for the Impairment or Disposal of Long-Lived Assets
. Management concurred with the assessment at that time. Our business and stock price may be adversely affected by these identified material weaknesses if such material weaknesses recur or if we have other material weaknesses in our internal controls.
Full 10-K form ▸
|
|
| related documents |
| 1123360--8/4/2006--GLOBAL_PAYMENTS_INC |
| 206030--2/20/2007--AXSYS_TECHNOLOGIES_INC |
| 206030--3/1/2006--AXSYS_TECHNOLOGIES_INC |
| 206030--2/17/2009--AXSYS_TECHNOLOGIES_INC |
| 1123360--7/30/2008--GLOBAL_PAYMENTS_INC |
| 920148--2/26/2009--LABORATORY_CORP_OF_AMERICA_HOLDINGS |
| 33619--12/21/2007--ESTERLINE_TECHNOLOGIES_CORP |
| 1052024--3/31/2006--EXTENDICARE_HEALTH_SERVICES_INC |
| 1018833--3/14/2008--QUADRAMED_CORP |
| 1123360--7/28/2009--GLOBAL_PAYMENTS_INC |
| 33619--12/24/2008--ESTERLINE_TECHNOLOGIES_CORP |
| 1018833--3/11/2009--QUADRAMED_CORP |
| 33619--1/8/2007--ESTERLINE_TECHNOLOGIES_CORP |
| 19584--2/26/2010--CHEMED_CORP |
| 1139463--12/15/2008--MEDCATH_CORP |
| 1139463--12/14/2006--MEDCATH_CORP |
| 1123360--7/30/2007--GLOBAL_PAYMENTS_INC |
| 893430--12/12/2006--PEDIATRIC_SERVICES_OF_AMERICA_INC |
| 829608--2/25/2010--PSYCHIATRIC_SOLUTIONS_INC |
| 1007330--3/23/2007--PRG_SCHULTZ_INTERNATIONAL_INC |
| 886171--3/10/2010--UNIVERSAL_HOSPITAL_SERVICES_INC |
| 1320414--3/30/2007--SELECT_MEDICAL_HOLDINGS_CORP |
| 1035688--3/28/2007--SELECT_MEDICAL_CORP |
| 874733--9/13/2007--MEDIWARE_INFORMATION_SYSTEMS_INC |
| 1035688--3/20/2006--SELECT_MEDICAL_CORP |
| 886171--3/12/2009--UNIVERSAL_HOSPITAL_SERVICES_INC |
| 19584--2/28/2007--CHEMED_CORP |
| 26076--12/9/2009--CUBIC_CORP_/DE/ |
| 1170650--3/3/2006--MEDCO_HEALTH_SOLUTIONS_INC |
| 1274057--2/25/2009--HOSPIRA_INC |
|